Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone

Hematology Journal

Volumn 5, Issue 6, 2004, Pages 475-479

  Alymara, Vasiliki ^a   Bourantas, Dimitrios ^a   Chaidos, Aristeidis ^a   Bouranta, Paraskevi ^a   Gouva, Maria ^a   Vassou, Amalia ^a   Tzouvara, Evagelia ^a   Bourantas, Konstantinos L ^a,b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b NONE   (Greece)

Author keywords

thalassemia; Deferiprone; Deferoxamine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ASPARTATE AMINOTRANSFERASE; DEFERIPRONE; DEFEROXAMINE; FERRITIN; IRON CHELATING AGENT; METOCLOPRAMIDE; RANITIDINE; RIBAVIRIN;

ADULT; ANOREXIA; ARTHROPATHY; ARTICLE; BODY WEIGHT DISORDER; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HUMAN; IRON CHELATION; IRON URINE LEVEL; LIVER DYSFUNCTION; MALE; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; TASTE DISORDER; THALASSEMIA MAJOR; TREATMENT OUTCOME; VISUAL IMPAIRMENT; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BETA-THALASSEMIA; DEFEROXAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FERRITINS; HUMANS; INJECTIONS, SUBCUTANEOUS; IRON; IRON CHELATING AGENTS; MALE; MIDDLE AGED; PYRIDONES; TREATMENT OUTCOME;

EID: 11044238013     PISSN: 14664860     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.thj.6200550     Document Type: Article

References (24)

1. Zurlo MG, De Stefano P, Borgna-Pignatti C, Di Palma A, Piga A, Melevendi C et al. Survival and causes of death in thalassemia major. Lancet 1989; 8653: 27-30.
2. Giardina PJ, Grady RW. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol 2001; 38: 360-366.
3. Brittenham GM, Griffith PM, Nienhuis AW, Mc Laren CE, Young NS, Tucker EE et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331: 567-573.
4. Wolfe L, Olivieri N, Sallan D, Colan S, Rose V, Propper R et al. Prevention of cardiac disease by subcutaneous deferoxamine in patients with thalassemia major. N Engl J Med 1985; 312: 1600-1603.
5. Porter JB, Huehns ER. The toxic effects of desferrioxamine. Baillieres Haematol 1989; 2: 459-474.
6. Olivieri NF, Buncic JR, Chew E, Gallant T, Harrison RV, Keenan N et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986; 314: 869-873.
7. Olivieri NF, Brittenham GM, Matsui D, Berkovitch M, Blendis LM, Cameron RG et al. Iron-chelation therapy with oral deferiprone in patients with thalassemia major. N Engl J Med 1995; 332: 918-922.
8. Olivieri NF, Brittenham GM, McLaren CE, Templeton DM, Cameron RG, Mc Clelland RA et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339: 417-423.
9. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety protile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 2000; 108: 305-312.
10. Ceci A, Baiardi P, Felisi M, Cappelini MD, Camelli V, De Sanctis V et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002; 118: 330-336.
11. Al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P et al. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995; 91: 224-229.
12. Taher A, Sheikh-Taha M, Koussa S, Inati A, Neeman R, Mourad F. Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients. Eur J Haematol 2001; 67: 30-34.
13. Link G, Konijn AM, Breuer W, Cabantchik ZI, Hershko C. Exploring the 'iron Shuttle' hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in cluture. J Lab Clin Med 2001; 138: 130-138.
14. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103: 361-364.
15. Balveer K, Pryor K, Wonke B. Combined oral and parenteral iron chelation in beta thalassaemia major. Med J Malaysia 2001; 55: 493-497.
16. Mourad FH, Hoffbrand AV, Sheikh-Taha M, Koussa S, Khonaty AI, Taher A et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003; 121: 187-189.
17. Metaxa-Athanassiou M, Kousi A, Hatzipantelis E, Tsatra I, Ikonomou M, Perifanis V et al. Combined chelation with deferiprone and desferrioxamine in iron overloaded β-thalassemia patients. Haematologica 2004; 89: ELT07.
18. Kassou C, Ladis V, Berdoussi H, Papasotiriou I, Kattamis C. Safety and efficacy of combining deferiprone and deferoxamine in iron chelation therapy in patients with thalassemia. Blood 2002; 100: 120a.
19. Alymara V, Bourantas DK, Chaidos A, Hatzimichael EC, Vergos A, Dimos GA et al. Combined iron chelation therapy with desferrioxamine and deferiprone in β-thalassemic patients. Hematol J 2002; 3 (Suppl): 81a.
20. Farmaki K, Anagnostopoulos G, Platis O, Gotsis E, Toulas P. Combined chelation therapy in patients with thalassemia major: a fast and effective method of reducing ferritin levels and cardiological complications. Hematol J 20Q; 3 (Suppl 1): 79a.
21. Galanello R, Doneddu I, Dessi E. Iron chelation in thalassemia major: combined treatment with deferiprone and deferoxamine (abstract). Eleventh International Conference on Oral Chelation in the Treatment of Thalassemia and Other Diseases, Catania, 2001, p. 73a.
22. Pati HP, Choudhry VP. Deferiprone (L1) associated neutropenia in beta thalassemia major: an Indian experience. Eur J Haematol 1999; 63: 267-268.
23. Berkovitch M, Laxer RM, Inman R, Koren G, Printzker KP, Fritzler MJ et al. Arthropathy in thalassaemia patients receiving deferiprone. Lancet 1994; 343: 1471-1472.
24. Hoffbrand AV, AL-Refaie F, Davis B, Siritanakatkul N, Jackson FAB, Cochrane J et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998; 91: 295-300.